Jun 3, 2025, 12:50
Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL
Agenus shared a post about the collaboration with Zydus Group on LinkedIn:
“Agenus and Zydus Group announced a $141M strategic collaboration to advance the manufacturing and global development of BOT/BAL. This partnership combines Agenus’ immuno-oncology leadership with Zydus’ global manufacturing and commercial expertise to expand access to cancer immunotherapies in India and beyond.
Tune in to the webcast at 4:30pm ET today to hear from company executives.”
Steven O’Day, Chief Medical Officer at Agenus, added a comment about the collaboration:
“Proud to share this important announcement and partnership as we rapidly move BOT and BAL forward with focus and passion, leveraging the power of the immune system to deliver deep and durable responses in the advanced cancer and early cancer settings across tumor types that did not participate in the first IO Revolution!”
Read more.
Discover the latest insights on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 25, 2025, 05:53
Jun 25, 2025, 05:40